242 related articles for article (PubMed ID: 17074588)
1. Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma.
Xu X; Liu Y; Huang S; Liu G; Xie C; Zhou J; Fan W; Li Q; Wang Q; Zhong D; Miao X
Cancer Genet Cytogenet; 2006 Nov; 171(1):31-8. PubMed ID: 17074588
[TBL] [Abstract][Full Text] [Related]
2. Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C.
Flores-Contreras L; Sandoval-Rodríguez AS; Mena-Enriquez MG; Lucano-Landeros S; Arellano-Olivera I; Alvarez-Álvarez A; Sanchez-Parada MG; Armendáriz-Borunda J
BMC Gastroenterol; 2014 Jul; 14():131. PubMed ID: 25064094
[TBL] [Abstract][Full Text] [Related]
3. Comparative assessment of CacyBP/SIP, β-catenin and cannabinoid receptors in the adrenals of hypertensive rats.
Smereczańska M; Domian N; Lewandowska A; Kasacka I
J Cell Mol Med; 2024 May; 28(10):e18376. PubMed ID: 38780511
[TBL] [Abstract][Full Text] [Related]
4. Cannabinoid receptor, CB1, expression follows neuronal differentiation in the early chick embryo.
Begbie J; Doherty P; Graham A
J Anat; 2004 Sep; 205(3):213-8. PubMed ID: 15379926
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy.
Vara D; Salazar M; Olea-Herrero N; Guzmán M; Velasco G; Díaz-Laviada I
Cell Death Differ; 2011 Jul; 18(7):1099-111. PubMed ID: 21475304
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoid receptor 1 promotes hepatocellular carcinoma initiation and progression through multiple mechanisms.
Mukhopadhyay B; Schuebel K; Mukhopadhyay P; Cinar R; Godlewski G; Xiong K; Mackie K; Lizak M; Yuan Q; Goldman D; Kunos G
Hepatology; 2015 May; 61(5):1615-26. PubMed ID: 25580584
[TBL] [Abstract][Full Text] [Related]
7. Modulation of the tumor microenvironment and inhibition of EGF/EGFR pathway: novel anti-tumor mechanisms of Cannabidiol in breast cancer.
Elbaz M; Nasser MW; Ravi J; Wani NA; Ahirwar DK; Zhao H; Oghumu S; Satoskar AR; Shilo K; Carson WE; Ganju RK
Mol Oncol; 2015 Apr; 9(4):906-19. PubMed ID: 25660577
[TBL] [Abstract][Full Text] [Related]
8. A combined preclinical therapy of cannabinoids and temozolomide against glioma.
Torres S; Lorente M; Rodríguez-Fornés F; Hernández-Tiedra S; Salazar M; García-Taboada E; Barcia J; Guzmán M; Velasco G
Mol Cancer Ther; 2011 Jan; 10(1):90-103. PubMed ID: 21220494
[TBL] [Abstract][Full Text] [Related]
9. The use of cannabinoids as anticancer agents.
Velasco G; Hernández-Tiedra S; Dávila D; Lorente M
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():259-66. PubMed ID: 26071989
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of colon carcinogenesis by a standardized Cannabis sativa extract with high content of cannabidiol.
Romano B; Borrelli F; Pagano E; Cascio MG; Pertwee RG; Izzo AA
Phytomedicine; 2014 Apr; 21(5):631-9. PubMed ID: 24373545
[TBL] [Abstract][Full Text] [Related]
11. Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis.
McAllister SD; Murase R; Christian RT; Lau D; Zielinski AJ; Allison J; Almanza C; Pakdel A; Lee J; Limbad C; Liu Y; Debs RJ; Moore DH; Desprez PY
Breast Cancer Res Treat; 2011 Aug; 129(1):37-47. PubMed ID: 20859676
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of anti-invasion effect of cannabinoids on human hepatocarcinoma cells.
Pourkhalili N; Ghahremani MH; Farsandaj N; Tavajohi S; Majdzadeh M; Parsa M; Lavasani NJ; Ostad SN
Toxicol Mech Methods; 2013 Feb; 23(2):120-6. PubMed ID: 22978792
[TBL] [Abstract][Full Text] [Related]
13. Cannabis in cancer care.
Abrams DI; Guzman M
Clin Pharmacol Ther; 2015 Jun; 97(6):575-86. PubMed ID: 25777363
[TBL] [Abstract][Full Text] [Related]
14. Involvement of PPARγ in the antitumoral action of cannabinoids on hepatocellular carcinoma.
Vara D; Morell C; Rodríguez-Henche N; Diaz-Laviada I
Cell Death Dis; 2013 May; 4(5):e618. PubMed ID: 23640460
[TBL] [Abstract][Full Text] [Related]
15. Chemopreventive effect of the non-psychotropic phytocannabinoid cannabidiol on experimental colon cancer.
Aviello G; Romano B; Borrelli F; Capasso R; Gallo L; Piscitelli F; Di Marzo V; Izzo AA
J Mol Med (Berl); 2012 Aug; 90(8):925-34. PubMed ID: 22231745
[TBL] [Abstract][Full Text] [Related]
16. Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a Cannabis-derived non-psychotropic cannabinoid.
Borrelli F; Pagano E; Romano B; Panzera S; Maiello F; Coppola D; De Petrocellis L; Buono L; Orlando P; Izzo AA
Carcinogenesis; 2014 Dec; 35(12):2787-97. PubMed ID: 25269802
[TBL] [Abstract][Full Text] [Related]
17. The effects of cannabidiol and its synergism with bortezomib in multiple myeloma cell lines. A role for transient receptor potential vanilloid type-2.
Morelli MB; Offidani M; Alesiani F; Discepoli G; Liberati S; Olivieri A; Santoni M; Santoni G; Leoni P; Nabissi M
Int J Cancer; 2014 Jun; 134(11):2534-46. PubMed ID: 24293211
[TBL] [Abstract][Full Text] [Related]
18. Use of cannabinoid receptor agonists in cancer therapy as palliative and curative agents.
Pisanti S; Malfitano AM; Grimaldi C; Santoro A; Gazzerro P; Laezza C; Bifulco M
Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):117-31. PubMed ID: 19285265
[TBL] [Abstract][Full Text] [Related]
19. Differential role of cannabinoids in the pathogenesis of skin cancer.
Glodde N; Jakobs M; Bald T; Tüting T; Gaffal E
Life Sci; 2015 Oct; 138():35-40. PubMed ID: 25921771
[TBL] [Abstract][Full Text] [Related]
20. Cannabinoids inhibit cellular respiration of human oral cancer cells.
Whyte DA; Al-Hammadi S; Balhaj G; Brown OM; Penefsky HS; Souid AK
Pharmacology; 2010; 85(6):328-35. PubMed ID: 20516734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
